0001415889-25-021280.txt : 20250807 0001415889-25-021280.hdr.sgml : 20250807 20250807170006 ACCESSION NUMBER: 0001415889-25-021280 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250805 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donoghoe Nicholas CENTRAL INDEX KEY: 0001762951 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 251195136 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-08072025_050802.xml X0508 4 2025-08-05 0001551152 AbbVie Inc. ABBV 0001762951 Donoghoe Nicholas 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF BUS/STRAT OFFICER 0 Common Stock, $0.01 par value 2025-08-05 4 S 0 3234.17 198.27 D 68308 D Common Stock, $0.01 par value 2025-08-05 4 S 0 10061 198.59 D 58247 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.26 to $198.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This reflects shares acquired pursuant to a dividend reinvestment plan. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.56 to $198.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe 2025-08-07